Ocular Therapeutix clinical trials we track

Check company identity source

Phase 3 6 trials

TrialDrugs studiedStatusPrimary completion
Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 StudyNCT07516132OTX-TKIRecruiting2030-08-01Estimated
A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic RetinopathyNCT07235085Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24, Sham/mock procedure of intravitreal injection followed by a second sham/mock procedure at Week 24, Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24Recruiting2027-03Estimated
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular DegenerationNCT06495918Aflibercept, OTX-TKIActive not recruiting2027-01-08Estimated
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular DegenerationNCT06223958Aflibercept, OTX-TKI (axitinib implant)Active not recruiting2026-04-29Estimated
A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric CataractNCT04539548Dextenza Ophthalmic Insert, Prednisolone acetate ophthalmic suspension USP 1%Completed2023-12-21Actual
A Study to Evaluate the Long Term Safety of OTX-TP (Sustained Release Travoprost) Intracanalicular InsertNCT04061044Ophthalmic InsertCompleted2020-02-10Actual

A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy

RecruitingPrimary completion: 2027-03 · Estimated
Trial details
Registry ID
NCT07235085
Drugs studied
Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24, Sham/mock procedure of intravitreal injection followed by a second sham/mock procedure at Week 24, Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24

Phase 2 2 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Efficacy Outcome: IOP changes from Baseline. After: Measure: IOP Changes From Baseline in the Study Eye.

Check registry source